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A B S T R A C T
A Schiff base ligand 1 was prepared from condensation of salicyaldehyde with 2-amino-4-
phenyl-5-methyl thiazole. The ligand forms complexes with CoII, NiII, CuII, and ZnII in good
yield. The synthesized compounds were characterized by elemental analysis, magnetic sus-
ceptibility, molar conductance, infrared spectra, 1H and 13C NMR, mass, electronic absorption
and ESR spectroscopy. The anticancer activity of the synthesized compounds was studied
against different human tumor cell lines: breast cancer MCF-7, liver cancer HepG2, lung car-
cinoma A549 and colorectal cancer HCT116 in comparison with the activity of doxorubicin
as a reference drug. The study showed that ZnII complex showed potent inhibition against
human TRK in the four cell lines (HepG2, MCF7, A549, HCT116) by the ratio 80, 70, 61 and
64% respectively as compared to the inhibition in the untreated cells. Moreover, the mo-
lecular docking into TRK (PDB: 1t46) was done for the optimization of the aforementioned
compounds as potential TRK inhibitors.
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The chemistry of the Schiff base ligands and their metal com-
plexes has expanded enormously and encompasses a vast
area of organometallic compounds and various aspects of
bioinorganic chemistry (Abu-Diefa and Mohamed, 2015). Schiff
base ligands are considered “privileged ligands” because they
are mainly prepared by condensation between aldehydes and
primary amines (Chang et al., 2016). These ligands are able to
coordinate many different metals and to stabilize them in
various oxidation states (Ejidike and Ajibade, 2015). They are
used also as pigments and dyes, catalysts, intermediates in
organic synthesis, and as polymer stabilizers (Menati et al.,
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2013). Large numbers of Schiff bases have also been shown to
exhibit a broad range of biological activities, including anti-
tumor, anti-bacterial, fungicidal and anticarcinogenic properties
(Nagesh et al., 2015; Salehi et al., 2015; Shukla et al., 2013;
Zaltariov et al., 2015; Zayed and Zayed, 2015). Metal com-
plexes of Schiff bases with heterocyclic compounds also find
applications as potential drugs, (Andersen, 1999; Konstantinovic´
et al., 2003) due to the presence of multifunctional groups
(Chohan et al., 2004; Joseyphus et al., 2006; Vashi and Naik, 2004;
Venugopala and Jayashree, 2003). The excessive attention of
synthesizing determined broad range of N and S chelating
ligands as thiazole molecule have attracted significant inter-
est. This is because thiazoles have a great pharmacological
activity. Besides these atoms play an important role in the co-
ordination of metals at the active sites of various metal
biomolecules that have a therapeutic activity or serving as study
models for metallo-enzymes (Chen et al., 2012; Venkatraman
et al., 2010; Yenilmez et al., 2013). Thiazoles are very impor-
tant building blocks in medicinal chemistry and can be found
in numerous natural products (e.g. epothilone) and biologi-
cally important compounds including the anticancer drug
dasatinib, antiviral clinical candidate TMC435350 and anti-
diabetic drug candidate MB06322 (Dang et al., 2008; Doggrell,
2005; Erion et al., 2005; Lin et al., 2009). Recently, thiazoles found
application in drug development for the treatment of aller-
gies (Brzezin´ska et al., 2003), hypertension (Mishra et al., 2015),
inflammation (Sharma et al., 1998), schizophrenia (Jaen et al.,
1990), bacterial (Suzuki et al., 1994), HIV infections (Bell et al.,
1995), hypnotics (Ergenc et al., 1999), as fibrinogen receptor an-
tagonist with antithrombotic activity (Badorc et al., 1997) and
as new inhibitors of bacterial DNA gyrase B (Rudolph et al.,
2001).
Following all these observations and as a part of our con-
tinuing research on the coordination chemistry of multidentate
ligands (Abd-Elzaher, 2004a, 2004b; Abd-Elzaher et al., 2005, 2006,
2010, 2012a, 2012b; Fouda et al., 2008a, 2008b), we report here
the preparation and characterization of a Schiff base ligand
derived from condensation of salicyaldehyde with 2-amino-
4-phenyl-5-methyl thiazole. The study has been extended to
synthesize CuII, CoII, NiII and ZnII complexes with the pre-
pared ligand. All the prepared complexes have been
characterized by IR, 1H and 13C NMR, mass spectra, ESR, UV–
Vis, in addition to elemental analysis, molar conductivity and
magnetic susceptibility.
In the same direction and in continuing effort to find more
potent and selective anticancer compounds, herein, antican-
cer activity of the prepared compounds was carried out against
four different human tumor cell lines including breast cancer
cell line MCF-7, liver cancer cell line HepG2, lung carcinoma A549
and colorectal cancer HCT116 that may act through tyrosine
kinase (TRK) inhibition. Molecular Docking has been done to
evaluate the binding affinity of the Ni and Zn complexes to TRK.
2. Experimental
2.1. Materials and methods
All chemicals were obtained from Merck. Elemental analyses
were determined at the micro analytical center, Cairo University.
IR spectra were recorded in the 4000-400 cm−1 on a spectrom-
eter (Jasco FTIR- 6100 Japan), using KBr pellets. 1H and 13C NMR
were recorded on a Bruker DPX 300, δ values relative to the deu-
terated DMSO. Mass spectra: Jeol JMS-700 using FAB technique
with a 3-nitrobenzyl alcohol NBA matrix. Magnetic suscepti-
bilities were measured at 20 °C by the Gouy method at the
Faculty of Science, Cairo University. The molar conductance
measurements were measured in solution of the metal com-
plexes in DMF (10−3) using Metrohem 660 conductivity meter.
Electronic absorptions were recorded on a automatic spectro-
photometer (PG Instruments ltd., +80 + UV–Vis) in DMSO. ESR
measurements were made at approximately 298K with a Bruker
E500, X-band spectrometers operating at a frequency of 9.5 GHz
at National Institute for Standards, Giza.
2.2. Synthesis of the Schiff base ligand C17H14N2OS (1)
and metal complexes (2–5)
2-amino-4-phenyl-5-methyl thiazole (1 mmol, 2.95 g) dis-
solved in about 20 mL absolute ethanol was added slowly to
a magnetically stirred solution of salicyladehyde (1 mmol, 1.22 g),
in the presence of few drops of glacial acetic acid. The mixture
was refluxed for four hours. Then the solution was concen-
trated to its half volume then cooled; n-hexane was added to
the reaction mixture drop wise until a product began to pre-
cipitate. The formed product was filtered off, washed several
times with n-hexane, and recrystallized from ethanol. The dif-
ferent complexes were prepared by addition of 1 mmol of
CoCl2.6H2O, NiCl2.6H2O, CuCl2.2H2O and ZnCl2, dissolved in about
20 mL ethanol, into a solution of the ligand (2 mmol in 20 mL
ethanol). The mixture was refluxed for three hours, then the
solution was concentrated. The obtained solid products were
filtered, washed twice with cold n-hexane and dried.
2.3. Anticancer activity
2.3.1. Chemicals
Fetal bovine serum (FBS) and L-glutamine were obtained from
Gibco Invitrogen Company (Scotland, UK). Dulbecco’s modi-
fied Eagle’s medium (DMEM) was provided from Cambrex (New
Jersey, USA). Dimethyl sulfoxide (DMSO), doxorubicin, penicil-
lin, and streptomycin were obtained from Sigma Chemical
Company (Saint Louis, MO, USA). Human tyrosine kinase (TRK)
ELISA kit was purchase from Glory Science Co., Ltd (Del Rio,
TX 78840, USA).
2.3.2. Cell lines and culturing
Anticancer activity screening for the tested compounds uti-
lizing 4 different human tumor cell lines including breast cancer
cell line MCF-7, liver cancer cell line HepG2, lung carcinoma
A549 and colorectal cancer HCT116 were obtained from the
American Type Culture Collection (Rockville, MD, USA) through
LGC Standards GmbH, Wesel, Germany. The tumor cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat inactivated fetal calf serum
(GIBCO), penicillin (100 UmL−1) and streptomycin (100 μgmL−1)
at 37 °C in humidified atmosphere containing 5% CO2. Cells at
a concentration of 0.50 × 106 were grown in a 25 cm2 flask in
5 mL of complete culture medium.
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2.3.3. In vitro cytotoxicity assay
The antiproliferative activity was measured in vitro using the
Sulfo-Rhodamine-B stain (SRB) assay according to the previ-
ously reported standard procedure (Skehan et al., 1990). Cells
were inoculated in 96-well microtiter plate (104 cells per well)
for 24 hours before treatment with the tested compounds to
allow attachment of cell to the wall of the plate. Test com-
pounds were dissolved in DMSO at 1 mg mL−1 immediately
before use and diluted to the appropriate volume just before
addition to the cell culture. Different concentration of tested
compounds and doxorubicin (2, 5, 10 or 20 μg mL−1) were added
to the cells. Triplicate wells were prepared for each indi-
vidual dose. Monolayer cells were incubated with the prepared
compounds for 48 hours at 37 °C and in atmosphere of 5% CO2.
After 48 hours, cells were fixed, washed, and stained for 30 min
with 0.4% (w/v) SRB dissolved in 1% acetic acid. Unbound dye
was removed by four washes with 1% acetic acid, and the at-
tached stain was recovered by Tris-EDTA buffer. Color intensity
was measured in an ELISA reader. The relation between both
the surviving fraction and the drug concentration was plotted
to get the survival curve for each cell line after the specified
time. The concentration required for 50% inhibition of cell vi-
ability (IC50) was calculated and the results are given in Table 1.
The results were compared to the antiproliferative effects of
the reference control doxorubicin.
2.3.4. In vitro human tyrosine kinase (TRK) concentration
assay
The effect of tested compounds on the level of human tyro-
sine kinase (TRK) was determined in the four different human
tumor cell lines (MCF-7, HepG2, A549 and HCT116). The cells
at a concentration of 0.50 × 106 were grown in a 25 cm2 flask
in 5 mL of DMEM culture medium and were treated with 20 μl
of IC50 values of the compounds or the standard reference drug,
Doxorubicin dissolved in DMSO, then incubated for 24 h at 37 °C,
in a humidified 5% CO2 atmosphere. The cells were harvested
and homogenates were prepared in saline using a tight pestle
homogenizer until complete cell disruption.
To determine the level of TRK in samples, a double-antibody
sandwich enzyme-linked immunosorbent assay (ELISA) was
used. In brief, samples containing TRK were added to mono-
clonal antibody enzyme well which is pre-coated with human
TRK monoclonal antibody, incubation; then, add TRK antibod-
ies labeled with biotin, and combined with Streptavidin-HRP
to form immune complex; then carry out incubation and wash
again to remove the uncombined enzyme. Then add Chromo-
gen solution A, B, the color of the liquid changes into blue, and
at the effect of acid, the color finally becomes yellow. The
chroma of color and the concentration of the human TRK of
sample were positively correlated and the optical density was
determined at 450 nm. The level of TRK in samples was cal-
culated (pmol mL−1) as duplicate determinations from the
standard curve.
2.4. Molecular docking study
Molecular Operating Environment (MOE) 2008.10 (Moe source:
Chemical Computing Group Inc., Quebec, Canada, 2008) program
was used in molecular docking studies. Firstly, a Gaussian
Contact surface around the binding site was sketched, then the
surface enclosed the van Waals surface (we made filling in
solvent in accessible gaps). Finally docking studies were done
to assess the binding free energy of the inhibitor inside the
macromolecule. The Dock scoring in MOE software was done
utilizing London dG scoring function and has been upgrading
by using two unrelated refinement methods, the Grid-Min pose
and the Force-filed have been improved to check that refined
poses meet the specified conformations. Auto rotatable bonds
were allowed; the best ten binding poses were directed to analyze
for achieving the best score. To compare the docking poses to
the ligand in the co-crystallized structure and to obtain RMSD
of the docking pose database browser was used.
2.4.1. Preparation of ligands and target protein-tyrosine
kinase
The compound contributed in this study as ligands was studied
for their binding affinity into protein-tyrosin kinase (TRK). To
build a three dimensional model of the structures, molecular
builder tool in MOE was used. Energy minimization was carried
out through Force-Filed MMFF94X. Optimization was carried
out using gradient of 0.001 for determining the lowest energy
confirmation with most favorable geometry. The crystal struc-
tures of c-kit receptor protein-tyrosine kinase in complex with
STI-571 (Imatinib or Gleevec) were picked up from the Protein
Date Bank (PDB) (http://www.rcsb.org/pdb/explore/explore.do
?structureId=1T46) (PDB code: 1t46) (Mol et al., 2004). Partial
charges and Hydrogen atom were put on to the protein with
the protonation 3d application in MOE. This application is
carried out to assign position hydrogen atom in the macro-
molecule structures and ionization states.
2.4.2. Molecular modeling and analysis of the docked results
To rank the binding affinity of the synthesized compounds to
TRK protein the binding free energy and hydrogen bonds
between the ligand and amino acid in TRK were used. Evalu-
ation of the hydrogen bonds were done by measuring the
hydrogen bond length, which does not exceed 3.7 A°. In ad-
dition, RMSD of the co-crystal ligand position compared to the
Table 1 – Analytical and some physical characteristics for the prepared compounds.
No. Ligand/complexes Color M. wt. Calcd. (found) (%) AM Yield (%)
C H N
1 HL (C17H15N2SO) Yellow 295 69.13 (68.91) 5.12 (5.26) 9.48 (9.21) – 82
2 (C34H28CoN4O2S2) Greenish blue 647.6 63.05 (62.85) 4.36 (4.43) 8.65 (8.41) 16 65
3 (C34H28N4NiO2S2) Light brown 647.4 63.07 (62.85) 4.36 (4.32) 8.65 (8.52) 18 63
4 (C34H28CuN4O2S2) Brown 652.2 62.61 (62.26) 4.33 (4.2) 8.59 (8.48) 14 70
5 (C34H28N4O2S2Zn) Light yellow 654.1 62.43 (62.19) 4.31 (4.45) 8.57 (8.42) 11 64
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docking pose was used in ranking. Both RMSD as well as the
mode of interaction of the native ligand within the crystal struc-
ture of c-kite tyrosin kinase receptor were used as standard
docked model.
3. Results and discussion
The Schiff base ligand 1 was prepared from condensation of
salicyaldehyde with 2-amino-4-phenyl -5-methyl thiazole
(Scheme 1).The ligand and its metal complexes (1–5) were found
to be stable in air and light. All compounds 1–5 were soluble
in common organic solvents such as ethanol, methanol,
acetone, and chloroform.The elemental analysis confirmed that
all complexes 2–5 have 2:1 molar ratio between the ligand and
the metal. The elemental analyses of the compounds 1–5 were
consistent with the calculated results from the empirical
formula of each compound (Table 1).
3.1. IR spectra
The IR spectra of the compounds 1–5 were represented in
Table 2. The IR spectra of the prepared ligand 1, which showed
a strong band at 1632 cm−1, were assigned to the formation of
the azomethine (C=N) group (Abd-Elzaher, 2004a, 2004b;
Abd-Elzaher et al., 2005). The band at 1567 cm−1 was attrib-
uted to υcyclic(C=N) of thiazole ring (Venkatraman et al., 2010).
Phenolic C—O stretch band is observed at 1278 cm−1; another
medium band appeared at 753 cm−1, which was assigned to
C—S—C (ring) stretching vibration (Abd-Elzaher, 2004a, 2004b).
Another band was observed centered at 2987 cm−1, which
Scheme 1 – Preparation of the ligand and its complexes.
Table 2 – The IR spectral (cm−1) assignment for the ligand and its complexes.
No. Ligand/complexes (OH)hydrogen-bond C=N (C=N)thiazole C—O C—S—C M—O M—N
1 HL(C17H15N2OS) 2987 1632 1567 1278 753 – –
2 (C34H28CoN4O2S2) – 1611 1517 1261 758 502 424, 443
3 (C34H28N4NiO2S2) – 1615 1522 1256 754 500 421, 454
4 (C34H28CuN4O2S2) – 1606 1562 1257 749 492 428
5 (C34H28N4O2S2Zn) – 1612 1523 1263 757 529 422, 449
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indicate the presence of an intramolecular hydrogen bond in-
teraction between phenolic group with imine-nitrogen atom
(Nazır et al., 2000; Yıldız et al., 1998).
By comparing the IR spectra of complexes 2–5 with the spec-
trum of the free ligand, the disappearance of the intramolecular
hydrogen bond signal of the free ligand was observed, which
indicates the removal of the proton of hydroxyl group during
the chelation. This is further supported by the shift of C—O
band from 1278 cm−1 (in ligand) to 1256–1263 cm−1 (in com-
plexes) (Abd-Elzaher et al., 2005). However, the band due to the
azomethine (C=N) group in the free ligand (at 1632 cm−1) was
shifted to a lower frequency (1606–1615 cm−1) in the com-
plexes. This shift indicates coordination of the azomethine
nitrogen to the metal ions in the complexes. In addition, the
band due to υcyclic(C=N) of thiazole ring (in ligand) was shifted
in all complexes except Cu-complex; this shift indicates the
involvement of the thiazole nitrogen atom in the complex for-
mation (2,3,5) and not coordinated in the case of complex 4
(Bolos et al., 1999). The C—S—C band of the free ligand, which
appears at 753 cm−1, showed a very little effect by complex-
ation indicating that the sulfur atom is not involved in the
chelation (Nakamoto, 1998; Neelakantan et al., 2008; Omar and
Mohamed, 2005).Two new bands in the range 484–502 and 421–
454 cm−1 were also observed (Table 2). These two bands were
observed in the complexes and not found in the free ligand
and they are attributed to M—O and M—N bonds in the com-
plexes respectively (Rana et al., 1982).
3.2. NMR spectra
The 1H and 13C NMR spectra of the ligand and its ZnII complex
were recorded at room temperature using DMSO-d6 as a solvent
(Table 3). The 1H NMR spectra of the ligand showed a singlet
at δ2.38 ppm attributed to methyl group attached to the thia-
zole ring, and multiplet at δ 7.80–6.93 ppm due to aromatic
protons. The spectra showed also azomethine proton (CH=N)
as singlet at δ 9.19 ppm. The OH proton is observed as singlet
at δ 11.51 ppm. A comparison of the 1H NMR spectra of the ZnII
complex and the free ligand indicates that the proton signal
corresponding to OH group of ligand has disappeared in ZnII
complex, which may be due to deprotonation.The CH=N proton
in the ligand is shifted to 9.08 ppm in the ZnII complex, which
suggested that the azomethine nitrogen is involved in the co-
ordination (Maurya et al., 2005).
The 13C NMR of the ligand showed a signal at 16.3 ppm which
was assigned to the methyl group attached to the thiazole rings,
and three signals at 120.2, 141.4 and 159.4 ppm were as-
signed to the thiazole rings (Abd-Elzaher et al., 2012a, 2012b).
The signal that appeared at 152.2 ppm was assigned to the
carbon of the azomethine group. Signals due to phenyl carbons
appeared in the range of 117.4–164 ppm (Yıldız et al., 2010).The
13C NMR signals of the ZnII complex were shifted slightly
downfield compared with that of the ligand, which may be due
to coordination of the ligand with the metal ions (Abd-Elzaher
et al., 2012a, 2012b).
3.3. Molar conductivity measurements
The molar conductivities of 10−3 M of the complexes (dis-
solved in DMF) at room temperature were measured (Table 1).
The results were in the range 11–18 Ω−1.mol−1.cm2 for CoII, NiII,
CuII and ZnII complexes. Conductivity measurements reveal that
all the metal complexes have conductivity values in the range
characteristic for non-electrolytic nature (Andersen, 1999;
Chohan et al., 2004; Golcu et al., 2005; Joseyphus et al., 2006;
Vashi and Naik, 2004; Venugopala and Jayashree, 2003).
3.4. Electronic spectra and magnetic moment
The electronic absorption spectrum of the ligand showed three
bands at 272, 338 and 453 nm (Table 4). The first one may be
assigned to intra-ligand π–π* transition, which is nearly un-
changed on complexation, whereas the second and third bands
may be assigned to the n–π* and charge transfer transition of
the azomethine group and nitrogen atom of the thiazole ring
(Sreeja et al., 2004).
The electronic spectra of the CoII complex showed two bands
at 572 and 484 nm. These bands are assigned to the transi-
tions 4T1g(F) →4A2g(F) and 4T1g(F) →4T2g (P), respectively; the CoII
complex also showed magnetic moment at 4.6 B.M., which in-
dicates the presence of CoII complex in octahedral geometry
(Abd-Elzaher et al., 2012a, 2012b; Fouda et al., 2008a, 2008b).The
electronic absorption of NiII complex showed three bands at 595,
387 and 841 nm (Table 4).These bands are assigned to the tran-
sitions 3A2g (F) →3T1g (F), 3A2g→3T1g (p) and 3A2g→3T2g respectively
(Abd-Elzaher et al., 2006; El-Shiekh et al., 2006; Lever, 1984); the
magnetic moment of NiII complex was 3.2 B.M.These results sug-
gested the presence of octahedral geometry for NiII complex.The
electronic spectra of the CuII complex showed two bands at 642,
Table 3 – 1H and 13C NMR data of the ligand and its ZnII complex.
Ligand/ complex Ligand ZnII complex
1H NMR (DMSO-d6),
δ (ppm)
2.38(s, CH3 in thiazole ring), 6.93–7.80 (m,9 H,2Ph), 9.19(s,
1H, CH=N), 11.51(s, 1H, OH)




16.3 (CH3 attached to thiazole rings), 120.2, 141.6, 153.7
(thiazole rings), 148.2 (C=N), 117.4–164 (aromatic
carbons)
16.5 (CH3 attached to thiazole rings), 120.3, 141.6, 153.9
(thiazole rings), 149.1 (C=N), 118.4–164.3 (aromatic
carbons)
Table 4 – The electronic spectra and magnetic moments
for the ligand and its complexes.
No. Ligand/complexes Bands in DMSO μeff (BM)
1 HL(C17H15N2OS) 453, 338, 272 –
2 (C34H28CoN4O2S2) 572, 484, 453, 340, 270 4.6
3 (C34H28N4NiO2S2) 841, 595, 450, 387, 271 3.2
4 (C34H28CuN4O2S2) 624, 508, 452, 356, 270 1.81
5 (C34H28N4O2S2Zn) 450, 350, 270 Dia.
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508 nm, which are assigned to 2B1g→2A1g and 2B1g →2Eg transi-
tions respectively (Abd-Elzaher, 2004a, 2004b; Fouda et al., 2008a,
2008b), and the magnetic moment of CuII complex was 1.81 B.M.
Both the electronic spectra and the magnetic values proposed
the presence of the square planar geometry for CuII complex.
On the basis of the above observation and spectral data, it is
suggested that the CoII, NiII and ZnII complexes show octahe-
dral geometry structures; however, the CuII complex shows
square-planar geometry structure (Lever, 1984).
3.5. Mass spectra
The mass spectrum supports the proposed empirical formula
of the ligand. It reveals the molecular ion peak m/z at 294 con-
sistent with the molecular weight of the ligand. While the
fragments at m/z = 214, 201, 188, and 83 correspond to C12H12N3O,
C12H12N2O, C11H11N2O, and C4H3S, respectively. The mass spectra
of the complexes 2–5 show molecular ion peaks m/z at 648,
647, 652 and 654, consistent with the molecular weight of these
complexes, respectively.
3.6. Electron spin resonance spectra
The solid state ESR spectra of 4 exhibit axially symmetric
g-tensor parameters with gǁ <= g⊥ > 2.0023 indicating that the
copper site has a dx2-y2 ground-state characteristic of square
planar stereochemistry (El-Sonbati et al., 2011; Speie et al., 1996).
The spin Hamiltonian parameters of the complex at gǁ, g⊥, and
Aǁ have the values 2.157, 2.064, 2.095 and 207 × 10−4 cm−1, with
exchange interaction parameter (G) 4.6. A good indication of
square planar coordination geometry for the copper complex
moiety according to the gǁ and |Aǁ| values has been shown.
In addition, in axial symmetry, the g-values are related by
the expression G = (gǁ − 2)/(g⊥ − 2) = 4, where G is the ex-
change interaction parameter. According to Hathaway and
Billing (Diab et al., 2010; El-Sonbati et al., 2011; Hathaway and
Billing, 1970), if the value of G is greater than 4, the exchange
interaction between CuII centers in the solid state is negli-
gible, whereas when it is less than 4, a considerable exchange
interaction is indicated in the solid complex. The calculated
G values for 4 is 4.6 suggesting that there are no copper–
copper exchange interactions (Diab et al., 2010; El-Sonbati et al.,
2011; Hathaway and Billing, 1970; Speie et al., 1996).
3.7. Anticancer activity
Chemotherapy is the major approach for both localized and
metastasized cancer. Therefore, the synthesized compounds
were screened for their in vitro cytotoxicity and growth inhibi-
tory activities against 4 different human tumor cell lines
including breast cancer cell line MCF-7, liver cancer cell line
HepG2, lung carcinoma A549 and colorectal cancer HCT116.The
results were compared with the activity of the known anti-
cancer doxorubicin as a reference drug. The cytotoxicity of the
tested compounds was expressed by median growth inhibi-
tory concentration (IC50) which required producing 50% cytotoxic
effect against cancer cells after 48 hours exposure to tested
compounds. The screening results are given in Table 1.
It is evident that for the HepG2 and MCF-7 cells, all the
tested compounds showed anticancer activity with IC50 values
that ranged from 6.20 to 9.22 and from 6.00 to 10.00 μg mL−1
respectively (Table 5). It is clear from the data that the order
of cytotoxicity activity against the two cancer cell lines of
the tested compounds was ZnII complex, NiII complex, CuII
complex, CoII complex and (L)1 in descending order. While in
case of A549 cells, only ZnII complex and NiII complex showed
anticancer activity at IC50 of 5.30 and 9.10 μg mL−1 respec-
tively. In addition, HCT116 revealed anticancer activity for
L, CuII complex and ZnII complex with IC50 of 9.50, 6.70 and
6.20 μgmL−1 respectively. It is clear from the results that in all
four cell lines the cytotoxicity of ZnII complex showed a
strong activity compared with doxorubicin. Furthermore, to
elucidate the mechanism by which the prepared compounds
exert their antitumor activities, we estimated the level of
human TRK in the cancer cells treated with the prepared
compounds.
Tyrosive kinases (TRKs) are indispensable for numerous pro-
cesses in the cell. These enzymes catalyze phosphorylation of
different cellular substrates. Phosphorylation in turn regu-
lates various cellular functions. Normally, their activity is
stringently regulated. However, under pathological condi-
tions, TRKs can be deregulated, leading to alterations in the
phosphorylation and resulting in uncontrolled cell division, in-
hibition of apoptosis, and other abnormalities and consequently
to diseases (Shchemelinin et al., 2006a, 2006b). Various cancers
and other diseases are known to be caused or accompanied
by deregulation of the phosphorylation. Inhibition of TRKs has
Table 5 – The IC50 values and the percent of TRK of the tested compounds in 4 different human cancer cell lines.
Compound IC50 (μgmL−1) % of TRK inhibition*
HepG2 MCF-7 A549 HCT116 HepG2 MCF-7 A549 HCT116
L (ligand) 9.22 10.00 – 9.50 19 6.5 – 18
CoII complex 8.16 9.11 – – 33 19 – –
NiII complex 7.20 7.30 9.10 – 73 55 38.5 –
CuII complex 7.50 8.70 – 6.70 67 33 – 43
ZnII complex 6.20 6.00 5.30 6.20 80 70 61 64
DMSO – – – – – – – –
Doxorubicin 4.20 4.40 4.70 5.25 81 84 83.5 83
Data were expressed as average of three independent experiments.
The percentage changes as compared with control untreated cells (DMSO treated).
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been shown to be a promising therapeutic strategy. Many TRK
inhibitors (TRKs) have been produced and tested in clinic by
now. These molecules have a low molecular weight and most
of them bind to protein kinases competing with ATP for the
ATP-binding site (Bogoyevitch et al., 2005). The availability of
newer inhibitors will be the main target of many researchers
in the future.
The results in Table 5 showed that most of the tested com-
pounds exhibited inhibitory potential against humanTRK. In case
of human liver cancer HepG2 NiII, CuII and ZnII complexes re-
vealed inhibition to TRK by 73, 67 and 80% as compared with
the untreated cancer cells, while doxorubicin showed 81% in-
hibition. In case of human breast cancer MCF7 NiII and ZnII
complexes were found to be potent inhibition against human
TRK by 55% and 70% respectively, while doxorubicin showed 84%
inhibition. Moreover, in case of human lung cancer A549, only
ZnII complex was found to be potent inhibition against human
TRK by 61% while doxorubicin showed 83.5% inhibition. Fur-
thermore, in case of colorectal cancer HCT116 CuII and ZnII
complexes were found to be potent inhibition against human
TRK by 43 and 64% respectively, while doxorubicin showed 83%
inhibition. It is clear that ZnII complex showed potent inhibi-
tion against humanTRK in the four cell lines (HepG2, MCF7,A549,
HCT116) by the ratio 80, 70, 61 and 64% respectively as com-
pared to the inhibition in the untreated cells as listed in Table 5.
The highest activity of the ZnII complex than the others may
be attributed to the function of the ZnII complex as a com-
petitive inhibitor of hemeoxygenase (HMOX1), which is
produced in large amounts in solid tumors (Huang et al., 2005),
in humans and animal tumor models. HMOX1 has been adapted
to defend against oxidative and other cellular stresses (Huang
et al., 2005).
3.8. Molecular modeling: docking study
3.8.1. Molecular modeling: docking study
The prepared compounds were analyzed for the binding af-
finity of tyrosine kinases receptor (PDB 1t46) for the purpose
of both find out the interaction between studied compounds
and c-kit receptor and for lead optimization. Molecular mod-
eling calculation was carried out to investigate the binding free
energies of these inhibitor inside the target c-kit kinase receptor.
Fig. 1 – The binding mode of the native ligand STI with C-kit exhibited one H-bond donor with THR 670 at distance 2.08 and
one H-bond donor with ILE 789 at distance 2.19 and one H-bond donor with CYS 673 at distance 2.85 and one H-bond
acceptor with HOH 1105 at distance 2.82 its score was −20.04 k.calmol−1.
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3.8.2. Validation of the docking performance and accuracy
Docking of the native co-crystallized STI-571 ligand (Imatinib
or Gleevec) was used to validate the docking accuracy of the
program. The docked ligand was exactly superimposed on the
native co-crystallized one with RMSD being 0.40 A´˚ and binding
free energies of −20.04 kcal.mol−1.The hydrogen bonds between
the amino acids and the docked ligand were the same as those
between the amino acid and the native ligand.
3.8.3. The binding affinities of the synthesized compounds
into c-kit kinase receptor
To compare affinity and to find out the interaction between
ligand and receptor, molecular docking study was done (Fig. 1).
For the docking calculation, firstly, the protein structure (PDB
code: 1t46) was detached from the inhibitor and hydrogen atoms
were added.The binding free energy, hydrogen bond and RMSD
were used to determine the binding affinity. All the prepared
Fig. 2 – The binding mode of the Zn-complex with C-kit receptor exhibited one H-bond acceptor with HOH 1105 at distance
2.64; and one H-bond acceptor with HOH 1105 at distance 2.63 and one H-bond acceptor with HOH 1106 at distance 3.32
and its score was −15.77 k.cal mol−1.
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Fig. 3 – The binding mode of the Ni-complex with C-kit exhibited one H-bond acceptor with HOH 1033 at distance 3.16 and
its score was −11.98 kcalmol−1.
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compounds were docked into the same binding site of the
native co-crystallized ligand. Both ZnII and NiII 5,3 respec-
tively, gave the best docking score (Figs. 1–3).
4. Conclusion
The Schiff-base ligand 1 (E)-2-(((5-methyl-4-phenylthiazol-2-
yl)imino)methyl)phenol was synthesized and determined with
different spectroscopic techniques, followed by synthesis of four
novel cobalt, nickel, copper and zinc complexes. The new com-
pounds were investigated for inhibition against human TRK
in vitro cytotoxicity for four human tumor cell lines. The ZnII
complex showed potent inhibition against human TRK in the
four cell lines (HepG2, MCF7, A549, HCT116) by the ratio 80, 70,
61 and 64% respectively as compared to the inhibition in the
untreated cells in comparison with the reference drug (doxo-
rubicin); also most of the tested compounds exhibited inhibitory
potential against human protein tyrosine kinase (PTK).The syn-
thesized compounds were investigated for the binding affinity
of tyrosine kinases receptor (PDB1t46). MOE (molecular mod-
eling environment) evaluated the binding free energies of these
inhibitors into the target c-kit kinase receptor. It was found that
the MOE were typically concise with the experimental data.
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